FDA grants priority review to Otsuka’s IgAN candidate sibeprenlimab
Sibeprenlimab, administered through subcutaneous injection, targets the APRIL protein associated with the development of IgAN, enabling patients to self-administer the treatment
FUJIFILM Diosynth secures $3bn manufacturing deal with Regeneron
Astellas, Pfizer’s Xtandi shows long-term benefits in prostate cancer
Celltrion secures FDA interchangeability designation for Yuflyma
England’s NICE recommends FILSPARI (sparsentan) as a treatment option for IgA nephropathy
FDA grants approval for Genentech’s Susvimo in diabetic retinopathy
Analysis
View More
Risks
View MoreSocietal polarisation and its impact on the pharmaceutical industry
Societal polarisation presents significant challenges for the pharmaceutical industry, affecting regulatory landscapes, public trust, innovation, and market dynamics
Effects of interstate armed conflicts on the pharmaceutical industry
Unveiling the impact of misinformation and disinformation in the pharmaceutical industry
The ripple effects of inflation on the pharmaceutical industry
Extreme weather events: The implications for the pharmaceutical industry